Wells Fargo raised the firm’s price target on uniQure (QURE) to $80 from $65 and keeps an Overweight rating on the shares. The firm notes positive takeaways from our webinar, with favorable key opinion leader views on 3-year data and confidence in patients seeking AMT-130 and centers finding ways to offer the product. Wells continues to see blockbuster opportunity driven by compelling product profile.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE: